Given these dynamics, combination therapy involving CCR2 antagonists and anti-PD-1 antibodies has shown greater efficacy in suppressing tumor growth and lung metastasis in solid cancer compared to control or monotherapy, highlighting the potential for targeted intervention in CCL2-mediated pathways to enhance cancer treatment outcomes (Weng et al., 2024; Lin et al., 2024). The gene discussed is CCR2; the disease is neoplasm.